Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Clonal hematopoiesis in elderly twins: concordance, discordance and mortality

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Skin colonization by circulating neoplastic clones in cutaneous T-cell lymphoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Low vs. high hemoglobin trigger for Transfusion in Vascular surgery (TV): a randomized clinical feasibility trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The preleukemic TCF3-PBX1 gene fusion can be generated in utero and is present in ≈0.6% of healthy newborns

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  5. Yet another susceptibility variant for ALL: what's next?

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  1. Increased risk of anemia, neutropenia and thrombocytopenia in people with HIV and well-controlled viral replication

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Blodsygdomme

    Publikation: Bidrag til bog/antologi/rapportBidrag til bog/antologiFormidling

  3. Transcranial Alternating Current Stimulation Has Frequency-Dependent Effects on Motor Learning in Healthy Humans

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Emanuele Zucca
  • Stephanie Rondeau
  • Anna Vanazzi
  • Bjorn Østenstad
  • Ulrich J M Mey
  • Daniel Rauch
  • Björn E Wahlin
  • Felicitas Hitz
  • Micaela Hernberg
  • Ann-Sofie Johansson
  • Peter de Nully Brown
  • Hans Hagberg
  • Andrés J M Ferreri
  • Andreas Lohri
  • Urban Novak
  • Thilo Zander
  • Hanne Bersvendsen
  • Mario Bargetzi
  • Walter Mingrone
  • Fatime Krasniqi
  • Stefan Dirnhofer
  • Stefanie Hayoz
  • Hanne Hawle
  • Simona Berardi Vilei
  • Michele Ghielmini
  • Eva Kimby
Vis graf over relationer

The SAKK 35/10 phase 2 trial, developed by the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group, compared the activity of rituximab vs rituximab plus lenalidomide in untreated follicular lymphoma patients in need of systemic therapy. Patients were randomized to rituximab (375 mg/m 2 IV on day 1 of weeks 1-4 and repeated during weeks 12-15 in responding patients) or rituximab (same schedule) in combination with lenalidomide (15 mg orally daily for 18 weeks). Primary end point was complete response (CR)/unconfirmed CR (CRu) rate at 6 months. In total, 77 patients were allocated to rituximab monotherapy and 77 to the combination (47% poor-risk Follicular Lymphoma International Prognostic Index score in each arm). A significantly higher CR/CRu rate at 6 months was documented in the combination arm by the investigators (36%; 95% confidence interval [CI], 26%-48% vs 25%; 95% CI, 16%-36%) and confirmed by an independent response review of computed tomography scans only (61%; 95% CI, 49%-72% vs 36%; 95% CI, 26%-48%). After a median follow-up of 4 years, significantly higher 30-month CR/CRu rates and longer progression-free survival (PFS) and time to next treatment (TTNT) were observed for the combination. Overall survival (OS) rates were similar in both arms (‡90%). Toxicity grade ‡3 was more common in the combination arm (56% vs 22% of patients), mainly represented by neutropenia (23% vs 7%). Addition of lenalidomide to rituximab significantly improved CR/CRu rates, PFS, and TTNT, with expected higher, but manageable toxicity. The excellent OS in both arms suggests that chemotherapy-free strategies should be further explored. This trial was registered at www.clinicaltrials.gov as #NCT01307605.

OriginalsprogEngelsk
TidsskriftBlood
Vol/bind134
Udgave nummer4
Sider (fra-til)353-362
Antal sider10
ISSN0006-4971
DOI
StatusUdgivet - 2019

ID: 57439528